176 related articles for article (PubMed ID: 7726490)
1. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Bartlett MS; Smith JW; Meshnick SR
Antimicrob Agents Chemother; 1995 Feb; 39(2):325-8. PubMed ID: 7726490
[TBL] [Abstract][Full Text] [Related]
2. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
3. A preliminary characterization of the Pneumocystis carinii dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Meshnick SR
J Eukaryot Microbiol; 1994; 41(5):92S. PubMed ID: 7804288
[No Abstract] [Full Text] [Related]
4. Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii organisms.
Kaneshiro ES; Sul D; Hazra B
Antimicrob Agents Chemother; 2000 Jan; 44(1):14-8. PubMed ID: 10602716
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
6. Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?
Kaneshiro ES
Drug Resist Updat; 2001 Oct; 4(5):322-9. PubMed ID: 11991686
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by atovaquone and bupravaquone but not by stigmatellin.
Kaneshiro ES; Sul D; Basselin M; Kayser O
J Eukaryot Microbiol; 2001; Suppl():172S-173S. PubMed ID: 11906049
[No Abstract] [Full Text] [Related]
8. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure.
Walker DJ; Wakefield AE; Dohn MN; Miller RF; Baughman RP; Hossler PA; Bartlett MS; Smith JW; Kazanjian P; Meshnick SR
J Infect Dis; 1998 Dec; 178(6):1767-75. PubMed ID: 9815231
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
[TBL] [Abstract][Full Text] [Related]
10. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Meshnick SR
Exp Parasitol; 1994 Aug; 79(1):50-6. PubMed ID: 8050525
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 1997 Jan; 39(1):45-51. PubMed ID: 9044027
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii.
Cirioni O; Giacometti A; Balducci M; Burzacchini F; Scalise G
J Antimicrob Chemother; 1995 Oct; 36(4):740-2. PubMed ID: 8591953
[No Abstract] [Full Text] [Related]
13. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.
Seymour KK; Lyons SD; Phillips L; Rieckmann KH; Christopherson RI
Biochemistry; 1994 May; 33(17):5268-74. PubMed ID: 7909690
[TBL] [Abstract][Full Text] [Related]
14. Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone.
Basselin M; Hunt SM; Abdala-Valencia H; Kaneshiro ES
Eukaryot Cell; 2005 Aug; 4(8):1483-92. PubMed ID: 16087753
[TBL] [Abstract][Full Text] [Related]
15. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
16. Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum.
Murphy AD; Lang-Unnasch N
Antimicrob Agents Chemother; 1999 Mar; 43(3):651-4. PubMed ID: 10049282
[TBL] [Abstract][Full Text] [Related]
17. Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.
Ball MD; Bartlett MS; Shaw M; Smith JW; Nasr M; Meshnick SR
Antimicrob Agents Chemother; 2001 May; 45(5):1473-9. PubMed ID: 11302813
[TBL] [Abstract][Full Text] [Related]
18. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
19. dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess.
Seymour KK; Yeo AE; Rieckmann KH; Christopherson RI
Ann Trop Med Parasitol; 1997 Sep; 91(6):603-9. PubMed ID: 9425362
[TBL] [Abstract][Full Text] [Related]
20. Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism.
Knecht W; Löffler M
FEBS Lett; 2000 Feb; 467(1):27-30. PubMed ID: 10664450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
